Rare Genetic Mutations Account for Nearly Half of Autism Cases

Quantitative study identifies 239 genes whose ‘vulnerability’ to devastating de novo mutation makes them priority research targets.

A team led by researchers at Cold Spring Harbor Laboratory (CSHL) this week publishes a new analysis in PNAS examining the genetics of autism spectrum disorder (ASD). Many researchers have proposed that ASD can arise from combinations of common, individually benign genetic variants. The new analysis supports an alternative view: that ultra‑rare, highly disruptive mutations in a specific set of vulnerable genes contribute substantially to autism risk.

The study identifies 239 genes whose susceptibility to likely gene‑disrupting (LGD) mutations marks them as high‑priority candidates for further research. LGD mutations are severe changes that can interrupt a gene’s function. When these occur de novo — appearing in the child but not present in either parent — they can have powerful effects on development and are overrepresented among ASD cases.

Although LGD mutations can undermine essential gene function, the investigators note a paradox: the genes implicated in autism tend to carry fewer overall mutations in the population than most human genes. The explanation lies in evolutionary dynamics. Devastating de novo LGD mutations that lead to severe ASD usually do not persist across generations, because individuals with severe forms of the disorder rarely reproduce. As a result, these damaging alleles are quickly removed from the gene pool, leaving the implicated genes with a relatively low background mutation burden.

Using quantitative methods, the team narrowed an initial list of roughly 500 probable causal genes to a focused set of 239 top candidate autism genes. This prioritized set helps researchers concentrate functional studies, genetic screening, and therapeutic exploration on genes most likely to play a causal role in ASD.

The analysis also clarifies how LGD mutations are transmitted within families. Working with data from the Simons Simplex Collection (SSC), the researchers observed that parents who carry potentially damaging LGD mutations but do not themselves show severe symptoms can nonetheless pass those mutations to their children. Such transmitted LGDs are more frequently observed in ASD‑affected offspring than in unaffected siblings, and these parental transmissions most often originate from the mother.

Researchers found further evidence to suggest that devastating “ultra-rare” mutations of genes that they classify as “vulnerable” play a causal role in roughly half of all ASD cases. Image is for illustrative purposes only.

These transmission patterns support a hypothesis first articulated in 2007 by senior author Michael Wigler and statistician Kenny Ye. Their unified theory proposed that unaffected mothers can act as carriers of highly damaging mutations that are preferentially transmitted to children who develop severe ASD. The phenomenon implies a sex‑dependent protective effect: females appear to tolerate certain mutations that are more likely to produce ASD when present in males. This is consistent with the well‑established male bias in ASD prevalence, where males are diagnosed at substantially higher rates than females.

In addition to observing biased parental transmission, the authors report that many of the rare, transmitted LGD mutations occur in genes expressed in the embryonic brain. This pattern aligns with models suggesting that some autism‑causing mutations disrupt genes that are essential for early brain development.

About this autism research

Funding: The work described here was supported by the Simons Foundation Autism Research Initiative.

Source: Cold Spring Harbor Laboratory
Image Source: The image is in the public domain
Original Research: The research “Low load for disruptive mutations in autism genes and their biased transmission” by Ivan Iossifov, Dan Levy, Jeremy Allen, Kenny Ye, Michael Ronemus, Yoon‑ha Lee, Boris Yamrom and Michael Wigler appears in PNAS. The study is led by Ivan Iossifov, a quantitative biologist at CSHL and the New York Genome Center.

Feel free to share this neuroscience article.